Regional perfusion in the treatment of patients with a locally metastasized malignant melanoma of the limbs
During the period 1964–1977, regional perfusion and wide local excision were used in the treatment of 104 patients with a locally metastasized malignant melanoma of the limbs. One hundred patients were considered in a study of 3-year and 5-year survival, which was 52% ( 52 100 ) and 38% ( 30 78 ), r...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer 1981-04, Vol.17 (4), p.471-476 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 476 |
|---|---|
| container_issue | 4 |
| container_start_page | 471 |
| container_title | European journal of cancer |
| container_volume | 17 |
| creator | Martijn, H. Oldhoff, J. Koops, H.Schraffordt |
| description | During the period
1964–1977, regional perfusion and wide local excision were used in the treatment of
104 patients with a locally metastasized malignant melanoma of the limbs. One hundred patients were considered in a study of
3-year and
5-year survival, which was
52% (
52
100
) and
38% (
30
78
), respectively. The
3-year and
5-year survival rates in
18 patients treated by normothermic perfusion prior to
1969 were
22% (
4
18
) and
17% (
3
18
), respectively; in
82 patients treated by hyperthermic perfusion after
1969, the
3-year survival was
58.5% (
48
82
) and the
5-year survival was
45% (
27
60
). The difference between the normothermic and hyperthemic group is significant at the
3-year and
5-year level (
P < 0.005 and
P < 0.025, respectively). The
5-year survival in those treated by hyperthermic perfusion was
42% in stage
II (
n = 12) and
46% in stage
III (
n = 48), the difference not being significant. The male
5-year survival was
36% (
8
22
), while the female was
53% (
20
38
). The
5-year survival for tumours of the arm and those of the leg was
23% (
3
13
) and
51% (
24
47
), respectively. No significancy could be demonstrated between these groups. Of the entire group of
100 patients,
35 developed a local recurrence after perfusion; in
11 there was simultaneous general metastazation as well. The recurrence developed within
2 years after perfusion in
27 (77%) patients and
16 (76%) died within
2 years of recurrence. |
| doi_str_mv | 10.1016/0014-2964(81)90257-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73746312</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0014296481902577</els_id><sourcerecordid>73746312</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-6ff9a5ddf1bbed375d3cec46b63409f353526218f970f6fc5569cfd417d292113</originalsourceid><addsrcrecordid>eNp9kE1rVTEQhrNQar36DxSyErs4mu_csxGk1FYoCFLXISeZtNHknGuSW2l_vTneS5fCwAyZed-ZPAi9oeQDJVR9JISKgY1KvN_Ss5EwqQf9DJ0-Pb9AL2v9SQjbCslO0InmnCkmTtGv73Abl9kmvIMS9rXXOM643QFuBWzLMDe8BLyzLfay4j-x3WGL0-JsSg84Q7O1R3wEj7NN8Xa2XZEh2XnJdpWuXinmqb5Cz4NNFV4f8wb9-HJxc341XH-7_Hr--XpwXOo2qBBGK70PdJrAcy09d-CEmhQXZAxcctlvp9swahJUcFKq0QUvqPZsZJTyDXp38N2V5fceajM5VgepnwTLvhrNtVCcsj4oDoOuLLUWCGZXYrblwVBiVq5mBWhWgGZLzT-uXb1Bb4_--ymDfxIdofb-p0Mf-ifvIxRTXYfnwMcCrhm_xP8v-AtSD4rH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73746312</pqid></control><display><type>article</type><title>Regional perfusion in the treatment of patients with a locally metastasized malignant melanoma of the limbs</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Martijn, H. ; Oldhoff, J. ; Koops, H.Schraffordt</creator><creatorcontrib>Martijn, H. ; Oldhoff, J. ; Koops, H.Schraffordt</creatorcontrib><description>During the period
1964–1977, regional perfusion and wide local excision were used in the treatment of
104 patients with a locally metastasized malignant melanoma of the limbs. One hundred patients were considered in a study of
3-year and
5-year survival, which was
52% (
52
100
) and
38% (
30
78
), respectively. The
3-year and
5-year survival rates in
18 patients treated by normothermic perfusion prior to
1969 were
22% (
4
18
) and
17% (
3
18
), respectively; in
82 patients treated by hyperthermic perfusion after
1969, the
3-year survival was
58.5% (
48
82
) and the
5-year survival was
45% (
27
60
). The difference between the normothermic and hyperthemic group is significant at the
3-year and
5-year level (
P < 0.005 and
P < 0.025, respectively). The
5-year survival in those treated by hyperthermic perfusion was
42% in stage
II (
n = 12) and
46% in stage
III (
n = 48), the difference not being significant. The male
5-year survival was
36% (
8
22
), while the female was
53% (
20
38
). The
5-year survival for tumours of the arm and those of the leg was
23% (
3
13
) and
51% (
24
47
), respectively. No significancy could be demonstrated between these groups. Of the entire group of
100 patients,
35 developed a local recurrence after perfusion; in
11 there was simultaneous general metastazation as well. The recurrence developed within
2 years after perfusion in
27 (77%) patients and
16 (76%) died within
2 years of recurrence.</description><identifier>ISSN: 0014-2964</identifier><identifier>DOI: 10.1016/0014-2964(81)90257-7</identifier><identifier>PMID: 7332624</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Chemotherapy, Cancer, Regional Perfusion ; Dactinomycin - therapeutic use ; Extremities ; Female ; Follow-Up Studies ; Hot Temperature - therapeutic use ; Humans ; Male ; Melanoma - mortality ; Melanoma - secondary ; Melanoma - therapy ; Melphalan - therapeutic use ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Sex Factors</subject><ispartof>European journal of cancer, 1981-04, Vol.17 (4), p.471-476</ispartof><rights>1981</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-6ff9a5ddf1bbed375d3cec46b63409f353526218f970f6fc5569cfd417d292113</citedby><cites>FETCH-LOGICAL-c357t-6ff9a5ddf1bbed375d3cec46b63409f353526218f970f6fc5569cfd417d292113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7332624$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martijn, H.</creatorcontrib><creatorcontrib>Oldhoff, J.</creatorcontrib><creatorcontrib>Koops, H.Schraffordt</creatorcontrib><title>Regional perfusion in the treatment of patients with a locally metastasized malignant melanoma of the limbs</title><title>European journal of cancer</title><addtitle>Eur J Cancer</addtitle><description>During the period
1964–1977, regional perfusion and wide local excision were used in the treatment of
104 patients with a locally metastasized malignant melanoma of the limbs. One hundred patients were considered in a study of
3-year and
5-year survival, which was
52% (
52
100
) and
38% (
30
78
), respectively. The
3-year and
5-year survival rates in
18 patients treated by normothermic perfusion prior to
1969 were
22% (
4
18
) and
17% (
3
18
), respectively; in
82 patients treated by hyperthermic perfusion after
1969, the
3-year survival was
58.5% (
48
82
) and the
5-year survival was
45% (
27
60
). The difference between the normothermic and hyperthemic group is significant at the
3-year and
5-year level (
P < 0.005 and
P < 0.025, respectively). The
5-year survival in those treated by hyperthermic perfusion was
42% in stage
II (
n = 12) and
46% in stage
III (
n = 48), the difference not being significant. The male
5-year survival was
36% (
8
22
), while the female was
53% (
20
38
). The
5-year survival for tumours of the arm and those of the leg was
23% (
3
13
) and
51% (
24
47
), respectively. No significancy could be demonstrated between these groups. Of the entire group of
100 patients,
35 developed a local recurrence after perfusion; in
11 there was simultaneous general metastazation as well. The recurrence developed within
2 years after perfusion in
27 (77%) patients and
16 (76%) died within
2 years of recurrence.</description><subject>Chemotherapy, Cancer, Regional Perfusion</subject><subject>Dactinomycin - therapeutic use</subject><subject>Extremities</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hot Temperature - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Melanoma - mortality</subject><subject>Melanoma - secondary</subject><subject>Melanoma - therapy</subject><subject>Melphalan - therapeutic use</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasm Staging</subject><subject>Sex Factors</subject><issn>0014-2964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1981</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1rVTEQhrNQar36DxSyErs4mu_csxGk1FYoCFLXISeZtNHknGuSW2l_vTneS5fCwAyZed-ZPAi9oeQDJVR9JISKgY1KvN_Ss5EwqQf9DJ0-Pb9AL2v9SQjbCslO0InmnCkmTtGv73Abl9kmvIMS9rXXOM643QFuBWzLMDe8BLyzLfay4j-x3WGL0-JsSg84Q7O1R3wEj7NN8Xa2XZEh2XnJdpWuXinmqb5Cz4NNFV4f8wb9-HJxc341XH-7_Hr--XpwXOo2qBBGK70PdJrAcy09d-CEmhQXZAxcctlvp9swahJUcFKq0QUvqPZsZJTyDXp38N2V5fceajM5VgepnwTLvhrNtVCcsj4oDoOuLLUWCGZXYrblwVBiVq5mBWhWgGZLzT-uXb1Bb4_--ymDfxIdofb-p0Mf-ifvIxRTXYfnwMcCrhm_xP8v-AtSD4rH</recordid><startdate>198104</startdate><enddate>198104</enddate><creator>Martijn, H.</creator><creator>Oldhoff, J.</creator><creator>Koops, H.Schraffordt</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198104</creationdate><title>Regional perfusion in the treatment of patients with a locally metastasized malignant melanoma of the limbs</title><author>Martijn, H. ; Oldhoff, J. ; Koops, H.Schraffordt</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-6ff9a5ddf1bbed375d3cec46b63409f353526218f970f6fc5569cfd417d292113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1981</creationdate><topic>Chemotherapy, Cancer, Regional Perfusion</topic><topic>Dactinomycin - therapeutic use</topic><topic>Extremities</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hot Temperature - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Melanoma - mortality</topic><topic>Melanoma - secondary</topic><topic>Melanoma - therapy</topic><topic>Melphalan - therapeutic use</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasm Staging</topic><topic>Sex Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martijn, H.</creatorcontrib><creatorcontrib>Oldhoff, J.</creatorcontrib><creatorcontrib>Koops, H.Schraffordt</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martijn, H.</au><au>Oldhoff, J.</au><au>Koops, H.Schraffordt</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Regional perfusion in the treatment of patients with a locally metastasized malignant melanoma of the limbs</atitle><jtitle>European journal of cancer</jtitle><addtitle>Eur J Cancer</addtitle><date>1981-04</date><risdate>1981</risdate><volume>17</volume><issue>4</issue><spage>471</spage><epage>476</epage><pages>471-476</pages><issn>0014-2964</issn><abstract>During the period
1964–1977, regional perfusion and wide local excision were used in the treatment of
104 patients with a locally metastasized malignant melanoma of the limbs. One hundred patients were considered in a study of
3-year and
5-year survival, which was
52% (
52
100
) and
38% (
30
78
), respectively. The
3-year and
5-year survival rates in
18 patients treated by normothermic perfusion prior to
1969 were
22% (
4
18
) and
17% (
3
18
), respectively; in
82 patients treated by hyperthermic perfusion after
1969, the
3-year survival was
58.5% (
48
82
) and the
5-year survival was
45% (
27
60
). The difference between the normothermic and hyperthemic group is significant at the
3-year and
5-year level (
P < 0.005 and
P < 0.025, respectively). The
5-year survival in those treated by hyperthermic perfusion was
42% in stage
II (
n = 12) and
46% in stage
III (
n = 48), the difference not being significant. The male
5-year survival was
36% (
8
22
), while the female was
53% (
20
38
). The
5-year survival for tumours of the arm and those of the leg was
23% (
3
13
) and
51% (
24
47
), respectively. No significancy could be demonstrated between these groups. Of the entire group of
100 patients,
35 developed a local recurrence after perfusion; in
11 there was simultaneous general metastazation as well. The recurrence developed within
2 years after perfusion in
27 (77%) patients and
16 (76%) died within
2 years of recurrence.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>7332624</pmid><doi>10.1016/0014-2964(81)90257-7</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-2964 |
| ispartof | European journal of cancer, 1981-04, Vol.17 (4), p.471-476 |
| issn | 0014-2964 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73746312 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Chemotherapy, Cancer, Regional Perfusion Dactinomycin - therapeutic use Extremities Female Follow-Up Studies Hot Temperature - therapeutic use Humans Male Melanoma - mortality Melanoma - secondary Melanoma - therapy Melphalan - therapeutic use Neoplasm Recurrence, Local Neoplasm Staging Sex Factors |
| title | Regional perfusion in the treatment of patients with a locally metastasized malignant melanoma of the limbs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T08%3A45%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Regional%20perfusion%20in%20the%20treatment%20of%20patients%20with%20a%20locally%20metastasized%20malignant%20melanoma%20of%20the%20limbs&rft.jtitle=European%20journal%20of%20cancer&rft.au=Martijn,%20H.&rft.date=1981-04&rft.volume=17&rft.issue=4&rft.spage=471&rft.epage=476&rft.pages=471-476&rft.issn=0014-2964&rft_id=info:doi/10.1016/0014-2964(81)90257-7&rft_dat=%3Cproquest_cross%3E73746312%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73746312&rft_id=info:pmid/7332624&rft_els_id=0014296481902577&rfr_iscdi=true |